Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Matthew W. McCarthy & Thomas J. Walsh. (2018) Candidemia in the cancer patient: diagnosis, treatment, and future directions. Expert Review of Anti-infective Therapy 16:11, pages 849-854.
Read now
Read now
Ya-Lin Chang, Shang-Jie Yu, Joseph Heitman, Melanie Wellington & Ying-Lien Chen. (2017) New facets of antifungal therapy. Virulence 8:2, pages 222-236.
Read now
Read now
Suganthini Krishnan Natesan & Pranatharthi H Chandrasekar. (2016) Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infection and Drug Resistance 9, pages 291-300.
Read now
Read now
Articles from other publishers (19)
Takahiro Matsuo, Sebastian Wurster, Ying Jiang, Koji Sasaki, Jeffrey Tarrand, Russell E Lewis & Dimitrios P Kontoyiannis. (2023) Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes. Journal of Antimicrobial Chemotherapy.
Crossref
Crossref
Reham Abdelmonem, Matthijs Backx, Lorna Vale, Brendan Healy & David Williams. (2022) Successful treatment of Mucor circinelloides in a Burn patient. Burns Open 6:2, pages 77-81.
Crossref
Crossref
Megha Sharma & Arunaloke Chakrabarti. 2022. Encyclopedia of Infection and Immunity. Encyclopedia of Infection and Immunity
348
362
.
Muhammad Umer Farooq, Ateeb Parvez, Mehwish Latif, Summera Moeen & Muhammad Ayaz Mir. (2021) Worse than hemophagocytosis: gastric mucor as deadly sequelae of immunosuppression in hemophagocytic lympo-histicytosis. European Journal of Gastroenterology & Hepatology 33:5, pages 763-764.
Crossref
Crossref
Huiping Huang, Helin Xie, Nupur Chaphekar, Ruichao Xu, Raman Venkataramanan & Xuemei Wu. (2021) A Physiologically Based Pharmacokinetic Analysis To Predict the Pharmacokinetics of Intravenous Isavuconazole in Patients with or without Hepatic Impairment. Antimicrobial Agents and Chemotherapy 65:5.
Crossref
Crossref
Harish C. Upadhyay. (2021) Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance. Current Topics in Medicinal Chemistry 21:8, pages 737-752.
Crossref
Crossref
Daniela Dalla Gasperina, Domenico Lombardi, Cristina Rovelli, Zaira Di Rosa, Valentina Lepera, Andreina Baj, Alice Nava, Gianluigi Lombardi & Paolo Antonio Grossi. (2019) Successful treatment with isavuconazole of subcutaneous phaeohyphomycosis in a kidney transplant recipient. Transplant Infectious Disease 21:6.
Crossref
Crossref
Frederic Lamoth & Dimitrios P. Kontoyiannis. (2019)
Therapeutic Challenges of Non-
Aspergillus
Invasive Mold Infections in Immunosuppressed Patients
. Antimicrobial Agents and Chemotherapy 63:11.
Crossref
Crossref
Caitlin R Rausch & Dimitrios P Kontoyiannis. (2018) Prolonged voriconazole treatment in a patient with chronic lymphocytic leukemia resulting in a litany of chronic overlapping toxicities. Journal of Oncology Pharmacy Practice 25:3, pages 747-753.
Crossref
Crossref
Márta Palkó, Mohamed El Haimer, Zsanett Kormányos & Ferenc Fülöp. (2019) Synthesis of Novel N-Heterocyclic Compounds Containing 1,2,3-Triazole Ring System via Domino, “Click” and RDA Reactions. Molecules 24:4, pages 772.
Crossref
Crossref
Xiaowei Zheng, Gaoqi Xu, Liqin Zhu, Luo Fang, Yiwen Zhang, Haiying Ding, Yinghui Tong, Jiao Sun & Ping Huang. (2018)
Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against
Aspergillus
spp. and
Candida
spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation
. The Journal of Clinical Pharmacology 58:10, pages 1266-1273.
Crossref
Crossref
Silke C. Mueller, Ilona Karasch, Johannes LaknerRainer Wacke. (2018) Validation of an Isavuconazole High-Performance Liquid Chromatography Assay in Plasma for Routine Therapeutic Drug Monitoring Applications. Therapeutic Drug Monitoring 40:4, pages 503-506.
Crossref
Crossref
Nikolaos V. Sipsas, Maria N. Gamaletsou, Amalia Anastasopoulou & Dimitrios P. Kontoyiannis. (2018) Therapy of Mucormycosis. Journal of Fungi 4:3, pages 90.
Crossref
Crossref
A. Kyvernitakis, H.A. Torres, Y. Jiang, G. Chamilos, R.E. Lewis & D.P. Kontoyiannis. (2016) Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clinical Microbiology and Infection 22:9, pages 811.e1-811.e8.
Crossref
Crossref
Maria N. Chitasombat & Dimitrios P. Kontoyiannis. (2016) Treatment of mucormycosis in transplant patients. Current Opinion in Infectious Diseases 29:4, pages 340-345.
Crossref
Crossref
Emmanuel Roilides & Charalampos Antachopoulos. (2016) Isavuconazole: an azole active against mucormycosis. The Lancet Infectious Diseases 16:7, pages 761-762.
Crossref
Crossref
Dimitrios Farmakiotis & Dimitrios P. Kontoyiannis. (2016) Mucormycoses. Infectious Disease Clinics of North America 30:1, pages 143-163.
Crossref
Crossref
Bingqing Liang, Lingjing Yuan, Yunyun Zhan, Mi Jin, Ermin Gu & Guoxin Hu. (2016) Determination of isavuconazole in rat plasma by UPLC-MS/MS: application to a pharmacokinetic study. Analytical Methods 8:25, pages 5025-5030.
Crossref
Crossref
Anna B. HalpernGary H. LymanThomas J. WalshDimitrios P. Kontoyiannis & Roland B. Walter. (2015) Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood 126:26, pages 2790-2797.
Crossref
Crossref